We investigated specific humoral and T-cell responses in people living with HIV (PLWH) before (T0), after two (T1) and after six months (T2) from the third dose of the BNT162b2 vaccine. Healthy donors (HD) were enrolled. The specific humoral response was present in most PLWH already after the second dose, but the third dose increased both the rate of response and its magnitude. Collectively, no significant differences were found in the percentage of responding T-cells between PLWH and HD. At T0, stratifying PLWH according to CD4 cell count, a lower percentage of responding T-cells in 200 cells/mu L one was observed. At T1, this parameter was comparable between the two subgroups, and the same result was found at T2. However, the pattern of co-expression of IFN gamma, IL2 and TNF alpha in PLWH was characterized by a higher expression of TNF alpha, independently of CD4 cell count, indicating a persistent immunological signature despite successful ART. mRNA vaccination elicited a specific response in most PLWH, although the cellular one seems qualitatively inferior compared to HD. Therefore, an understanding of the T-cell quality dynamic is needed to determine the best vaccination strategy and, in general, the capability of immune response in ART-treated PLWH.
Quality of t-cell response to SARS-CoV-2 mrrna vaccine in art-treated plwh / Tortellini, E.; Zingaropoli, M. A.; Mancarella, G.; Marocco, R.; Carraro, A.; Jamhour, M.; Barbato, C.; Guardiani, M.; Dominelli, F.; Pasculli, P.; Napoli, A.; Gaeta, A.; Mengoni, F.; Zuccala, P.; Belvisi, V.; Kertusha, B.; Parente, A.; Del Borgo, C.; Vullo, V.; Ciardi, M. R.; Mastroianni, C. M.; Lichtner, M.; LATINA COVID-19, Group. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 23:23(2022), pp. 1-14. [10.3390/ijms232314988]
Quality of t-cell response to SARS-CoV-2 mrrna vaccine in art-treated plwh
Tortellini E.;Zingaropoli M. A.
;Mancarella G.;Carraro A.;Guardiani M.;Dominelli F.;Pasculli P.;Napoli A.;Gaeta A.;Mengoni F.;Belvisi V.;Kertusha B.;Parente A.;Vullo V.;Ciardi M. R.;Mastroianni C. M.;Lichtner M.;
2022
Abstract
We investigated specific humoral and T-cell responses in people living with HIV (PLWH) before (T0), after two (T1) and after six months (T2) from the third dose of the BNT162b2 vaccine. Healthy donors (HD) were enrolled. The specific humoral response was present in most PLWH already after the second dose, but the third dose increased both the rate of response and its magnitude. Collectively, no significant differences were found in the percentage of responding T-cells between PLWH and HD. At T0, stratifying PLWH according to CD4 cell count, a lower percentage of responding T-cells in 200 cells/mu L one was observed. At T1, this parameter was comparable between the two subgroups, and the same result was found at T2. However, the pattern of co-expression of IFN gamma, IL2 and TNF alpha in PLWH was characterized by a higher expression of TNF alpha, independently of CD4 cell count, indicating a persistent immunological signature despite successful ART. mRNA vaccination elicited a specific response in most PLWH, although the cellular one seems qualitatively inferior compared to HD. Therefore, an understanding of the T-cell quality dynamic is needed to determine the best vaccination strategy and, in general, the capability of immune response in ART-treated PLWH.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tortellini_Quality_2022.pdf
accesso aperto
Note: Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.19 MB
Formato
Adobe PDF
|
2.19 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
